- Home
- COEP vs MCHX Comparison
COEP vs MCHX Comparison
Compare COEP & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | MCHX |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | 7 | 163 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 61.5M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | COEP | MCHX |
|---|---|---|
| Price | $11.72 | $1.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.8K | 11.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,291,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.32 | $1.26 |
| 52 Week High | $21.41 | $2.30 |
Technical Indicators
Market Signals| Indicator | COEP | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 36.09 |
| Support Level | $10.98 | $1.35 |
| Resistance Level | $13.23 | $1.76 |
| Average True Range (ATR) | 0.94 | 0.05 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 41.06 | 31.25 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About MCHX Marchex Inc. Class B
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.